Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Meto vs Sunlight.com

Meto
Graded #275

Lower grade

vs+23.400000000000006
Sunlight.com
Graded #7

Higher grade

The verdict

Sunlight.com takes it — 85.4/100 to 62/100.

Sunlight.com grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the cheapest published rates in the ranking — semaglutide $88/mo, tirzepatide $157/mo, flat and stated never to rise — from a LegitScript-certified telehealth with two named, NPI-verified physicians.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSunlight.com +47
45
92
Dose & formulationSunlight.com +38
40
78
Clinical oversightMeto +2
88
86
Labs & monitoringMeto +5
85
80
FulfillmentSunlight.com +21
67
88
Contract termsSunlight.com +33
55
88
Meto · left barSunlight.com · right bar

The numbers

MetricMetoSunlight.com
WeighScore62/10085.4/100
GradeCB
Scorecard rank#275#7
SemaglutideNot disclosed$88/mo
TirzepatideNot disclosed$157/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Meto

Graded #275 · C

Strengths

  • Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
  • Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
  • Matches patients with endocrinologists and obesity medicine specialists within minutes
  • Offers compounded semaglutide and tirzepatide with board-certified physician oversight
  • Handles all prior-auth paperwork; provider location pages exist for all 50 US states

Where it loses points

  • Medication pricing fully gated behind quiz — no public cash price for sema or tirz
  • Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
  • No LegitScript certification or named compounding pharmacy found on any public page
  • Company leadership and clinical team not disclosed publicly
  • Self-pay cash pricing exists per site copy but is not published anywhere
Sunlight.com

Graded #7 · B

Strengths

  • Cheapest published semaglutide in this ranking ($88/mo) with competitively priced tirzepatide ($157/mo), both flat and stated to never increase — not quiz-gated, the FAQ states the exact figures
  • LegitScript-certified with two named physicians and public NPI numbers (Lion MD network), rather than an anonymous "licensed clinicians" claim
  • No membership fee, cancel anytime, free shipping in 1-2 days, a fresh 4-week supply every month
  • All 50 states served, plus a separate live NAD+ program on the same domain

Where it loses points

  • Injection only — the hero banner's "Injections and oral options available" line does not match the live site: no oral GLP-1 product page exists and sunlight.com/oral-semaglutide/ 404s
  • The $157 tirzepatide figure sits inside a collapsed FAQ accordion rather than the hero, so it takes one extra click to find even though it is genuinely on the page
  • Sermorelin is marketed as "launching soon" and is not yet live — do not expect it today
  • No published lab or monitoring cadence, and the compounding pharmacy partner is referenced only generically, not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 509 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard